IFN-β was later approved in 1993 and is used to treat multiple sclerosis due to several overlapping mechanisms, such as decreasing the expression of major histocompatibility complex class II in antigen-presenting cells. The gene discussed is IFNB1; the disease is multiple sclerosis.